Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Compugen (Nasdaq: CGEN) announced it will release its Q3 2024 financial results on Tuesday, November 12, 2024, before U.S. markets open. The company will host a conference call and webcast at 8:30 AM ET to discuss financial results and provide a corporate update. Management will also discuss data presented at the Society for Immunotherapy of Cancer Annual Meeting (November 8-10, 2024). The conference call will be accessible via phone and live webcast through Compugen's website, with a replay available afterward.
Compugen (Nasdaq: CGEN) ha annunciato che pubblicherà i suoi risultati finanziari del Q3 2024 martedì 12 novembre 2024, prima dell'apertura dei mercati statunitensi. L'azienda organizzerà una conference call e un webcast alle 8:30 AM ET per discutere i risultati finanziari e fornire un aggiornamento aziendale. La direzione discuterà anche i dati presentati al Congresso Annuale della Società per l'Immunoterapia dei Tumori (8-10 novembre 2024). La conference call sarà accessibile tramite telefono e live webcast attraverso il sito di Compugen, con una registrazione disponibile successivamente.
Compugen (Nasdaq: CGEN) anunció que publicará sus resultados financieros del tercer trimestre de 2024 el martes 12 de noviembre de 2024, antes de la apertura de los mercados de EE. UU. La compañía llevará a cabo una conferencia telefónica y un webcast a las 8:30 AM ET para discutir los resultados financieros y proporcionar una actualización corporativa. La dirección también comentará los datos presentados en la Reunión Anual de la Sociedad para la Inmunoterapia del Cáncer (8-10 de noviembre de 2024). La conferencia telefónica será accesible por teléfono y por webcast en vivo a través del sitio web de Compugen, con una repetición disponible posteriormente.
컴퓨젠(나스닥: CGEN)은 미국 시장이 열리기 전에 2024년 11월 12일 화요일 2024년 3분기 재무 결과를 발표할 것이라고 발표했습니다. 회사는 재무 결과를 논의하고 회사 업데이트를 제공하기 위해 오전 8시 30분 ET에 컨퍼런스 콜과 웹캐스트를 개최할 예정입니다. 관리진은 또한 암 면역요법 학회 연례 회의(2024년 11월 8-10일)에서 발표된 데이터에 대해 논의할 것입니다. 컨퍼런스 콜은 전화 및 컴퓨젠 웹사이트를 통해 실시간 웹캐스트로 접근 가능하며, 이후 재생이 가능합니다.
Compugen (Nasdaq: CGEN) a annoncé qu'il publiera ses résultats financiers du T3 2024 le mardi 12 novembre 2024, avant l'ouverture des marchés américains. La société organisera une conférence téléphonique et un webcast à 8h30 ET pour discuter des résultats financiers et fournir une mise à jour sur l'entreprise. La direction discutera également des données présentées lors de la Réunion Annuelle de la Société pour l'Immunothérapie du Cancer (8-10 novembre 2024). La conférence téléphonique sera accessible par téléphone et en direct via le site Web de Compugen, avec une rediffusion disponible par la suite.
Compugen (Nasdaq: CGEN) gab bekannt, dass es seine Finanzergebnisse für das 3. Quartal 2024 am Dienstag, den 12. November 2024, vor der Eröffnung der US-Märkte veröffentlichen wird. Das Unternehmen wird um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten, um die Finanzergebnisse zu besprechen und ein Unternehmensupdate zu geben. Die Geschäftsleitung wird auch Daten präsentieren, die auf dem Jahrestreffen der Gesellschaft für Immuntherapie bei Krebs (8.-10. November 2024) vorgestellt wurden. Die Telefonkonferenz ist telefonisch und als Live-Webcast über die Website von Compugen zugänglich, mit einer anschließend verfügbaren Aufzeichnung.
- None.
- None.
HOLON,
As part of the update, management will discuss Compugen's data that will have been presented at the Annual Meeting of the Society for Immunotherapy of Cancer, being held on November 8-10, 2024.
To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S.,
or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following link.
Following the live webcast, a replay will be available on the Company's website.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which has been granted IND clearance from the FDA, is licensed to Gilead. Compugen is headquartered in
Company contact:
Yvonne Naughton, Ph.D.
VP, Head of Investor Relations, and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-release-third-quarter-2024-financial-results-on-tuesday-november-12-2024-302289893.html
SOURCE Compugen Ltd.
FAQ
When will Compugen (CGEN) release its Q3 2024 financial results?
What time is Compugen's (CGEN) Q3 2024 earnings call?
What will be discussed in Compugen's (CGEN) Q3 2024 earnings call?
